PMN 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• June 30, 2026, we had an accumulated deficit of $150.4 million. We had negative cash flows from operations of $22.8 million for the six months ended June 30, 2026.

• for, our product candidates, as well as continue and initiate new clinical trials, hire additional personnel, and pay fees to outside consultants, lawyers and accountants. In addition, if we obtain marketing approval for any product candidates, we may incur significant commercialization expenses rel…

• Safety will be a primary outcome with particular emphasis on assessing the expectation that, as a non-plaque binder, PMN310 will have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. PRECISE-AD will be the first study to examine the effects of a monoclona…

• To date, PMN310 has demonstrated a generally favorable safety profile, with no drug-related patient discontinuations and no treatment-related serious adverse events (SAEs) reported during the trial. On July 28, 2026, we reported positive blinded six-month interim safety and biomarker results from th…

• ●Hosted a webinar reporting positive blinded six-month interim safety and biomarker results from the PRECISE-AD Phase 1b study of PMN310, showing no ARIA-E across all genotypes in a population that included 61% APOE4 carriers (of which 11% were homozygotes), total ARIA of 4.4% (all mild and asymptom…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• commercialization expenses related to product manufacturing, marketing, sales and distribution. We may also incur expenses in connection with the in-licensing or acquisition of additional product candidates.

• To date, PMN310 has demonstrated a generally favorable safety profile, with limited patient discontinuations and no treatment-related serious adverse events (SAEs) reported during the trial. Based on current clinical trial patient visit schedules, we expect to complete the six-month assessments in t…

• Safety will be a primary outcome with particular emphasis on assessing the expectation that, as a non-plaque binder, PMN310 will have a reduced risk of ARIA. The study is powered to provide 95% confidence for detection of ARIA. The study has been designed with a sample size intended to provide suffi…

• ●In February 2026, we closed a private placement led by distinguished biotechnology investors for gross up-front proceeds of $75.5 million.

• ●Presentation and participation at Bloom Burton & CO Healthcare Investor Conference by Neil Warma, CEO

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• corporate issuers with low credit risk. Cash held is not subject to any external restrictions. As of the year ended December 31, 2025 and three months ended March 31, 2026, a hypothetical 10% relative change in interest rates would not have a material impact on our Financial Statements.

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in this Quarterly Report on Form 10-Q…

• to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding any required disclosure. We believe that a control system, no matter how well designed and operated, cannot provide absolute assurance that the objectives of the control system a…

• There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, that occurred during the three months ended June 30, 2026 that have materially affected, or are rea…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• Based on this evaluation, our principal executive officer and principal financial and accounting officer have concluded that our disclosure controls and procedures were effective to provide reasonable assurance that the information required to be disclosed by us in this Quarterly Report on Form 10-Q…

• There have been no changes in our internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, that occurred during the three months ended March 31, 2026 that have materially affected, or are re…

相对上期新增的文字 · 来源:10-Q · 2026-08-13

• We operate in a rapidly changing environment that involves a number of risks which could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this Quarterly Report on Form 10-Q, the risks and un…

相对上期删除的文字 · 来源:10-Q · 2026-05-12

• We operate in a rapidly changing environment that involves a number of risks which could materially affect our business, financial condition or future results, some of which are beyond our control. In addition to the other information set forth in this Quarterly Report on Form 10-Q, the risks and un…

• Factors Summary” and in Item 1A – “Risk Factors” in the Company’s Form 10-K, as amended and supplemented by the information in “Part II, Item 1A. Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026. The risk factors set forth below are risk factors containing chan…